Diagnosis and Genotype-Phenotype Correlations in Early Life Epilepsy and CDKL5 Disorder
Diagnosis and Genotype-Phenotype Correlations in Early Life Epilepsy and CDKL5 Disorder
批准号:
10758725
负责人:
Heather Elisa Olson
金额:
$23.13万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-01-01 至 2024-03-31
关键词:
AwardBasic ScienceBostonCDKL5 disorderChildChildhoodClinical ResearchClinical SciencesClinical TrialsClinical Trials DesignCollaborationsDevelopmentDiagnosisDiseaseDoctor of MedicineEpidemiologyEpilepsyGeneticGenetic DiseasesGenetic Predisposition to DiseaseGenotypeGoalsInterdisciplinary StudyInternationalIntractable EpilepsyKnowledgeLeadLeadershipLifeMaster of Public HealthMedicalMentorsMorbidity - disease rateMuscle hypotoniaNatureNeonatalNeurologistPediatric HospitalsPhenotypePrecision therapeuticsPrognosisRare DiseasesRefractoryResearchScienceSpasmSyndromeTrainingTranslational ResearchVulnerable PopulationsWorkclinical careclinical diagnosisclinical epidemiologyclinically relevantcortical visual impairmentdesigndevelopmental diseaseexperienceinfancymedical schoolsmortalitymultidisciplinaryneurogeneticsprogramsresearch studyresponseskillsstandard caretargeted treatmenttranslational approach
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
As an academic pediatric neurologist focusing on epilepsy genetics, the goal of this training award is to expand
Dr. Olson's training in clinical research approaches for study of rare early life genetic epilepsies and genotype-
phenotype correlations. Further it aims to advance her leadership skills, focused knowledge in epilepsy
genetics and CDKL5 disorder as well as her skills to develop and lead multidisciplinary research collaborations
for translational research. Training will include clinical trials design to facilitate advancement to next steps in
rare disease research as she develops an independent multidisciplinary research program focused on CDKL5
disorder and other rare genetic epilepsies. The proposed training expands on Dr. Olson's prior training in
epilepsy and neurogenetics, research experience including an NSADA award, and training in clinical research
and epidemiology. This work will uniquely bring together a multidisciplinary network of collaborators, allowing
basic science to impact clinical care and clinical research to focus basic science research on clinically relevant
questions.
Dr. Olson's primary mentor Annapurna Poduri, M.D., M.P.H., Director of our Epilepsy Genetics Program, will
provide guidance in clinical research, genotype-phenotype correlations, translational approaches, and
consortium science. Co-mentors Tim Benke, M.D., Ph.D and Elizabeth Engle, M.D. each add unique
experience in CDKL5 disorder and neurogenetics research, respectively. The work will be done primarily at
Boston Children's Hospital and Harvard Medical School. Dr. Olson directs one of three Centers of Excellence
for CDKL5 disorder, and has access to a local, national and international network of excellent clinical and basic
science collaborators to assist in this work.
Neonatal and infantile onset epilepsy results in significant morbidity and mortality. There are increasingly
identified genetic etiologies. CDKL5 disorder is one established early life epilepsy syndrome notable for being
associated with particularly refractory epilepsy, a severe developmental disorder, hypotonia and cerebral visual
impairment. Robust phenotype characterization and assessment of genotype-phenotype correlations of genetic
epilepsies, including CDKL5 disorder, is needed as a step towards rational precision therapy. Given its
refractory nature, a scientifically driven approach to understanding and treatment will be critical in CDKL5
disorder. The proposed research study aims to 1) determine predictors and define epidemiology of CDKL5
disorder, 2) establish genotype-phenotype correlations in CDKL5 disease, and 3) evaluate response of
CDKL5-associated epileptic spasms to standard treatments.
期刊论文(17)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Early diagnosis and experimental treatment with fenfluramine via the Investigational New Drug mechanism in a boy with Dravet syndrome and recurrent status epilepticus.
通过研究新药机制对患有 Dravet 综合征和复发性癫痫持续状态的男孩进行早期诊断和实验性治疗。
DOI:
10.1684/epd.2021.1345
发表时间:
2021-12-01
期刊:
Epileptic disorders : international epilepsy journal with videotape
影响因子:
--
作者:
[Trowbridge S, Poduri A, Olson H]
通讯作者:
Olson H
Towards understanding genetic risk in febrile seizures: innate immunity and neuronal excitability.
了解热性惊厥的遗传风险:先天免疫和神经元兴奋性。
DOI:
10.1093/brain/awac036
发表时间:
2022
期刊:
Brain : a journal of neurology
影响因子:
--
作者:
[Olson,HeatherE, Poduri,Annapurna]
通讯作者:
Poduri,Annapurna
DOI:
10.1016/s1474-4422(22)00035-7
发表时间:
2022-06
期刊:
LANCET NEUROLOGY
影响因子:
48
作者:
[Leonard, Helen, Downs, Jenny, Benke, Tim A., Swanson, Lindsay, Olson, Heather, Demarest, Scott]
通讯作者:
Demarest, Scott
CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment.
CDKL5 缺乏症相关癫痫:当前和新兴治疗的回顾。
DOI:
10.1007/s40263-022-00921-5
发表时间:
2022-06
期刊:
CNS drugs
影响因子:
6
作者:
[]
通讯作者:
Epileptic spasms in CDKL5 deficiency disorder: Delayed treatment and poor response to first-line therapies.
CDKL5 缺乏症中的癫痫痉挛:治疗延迟且对一线治疗反应不佳。
DOI:
10.1111/epi.17630
发表时间:
2023
期刊:
Epilepsia
影响因子:
5.6
作者:
[Olson,HeatherE, Demarest,Scott, Pestana-Knight,Elia, Moosa,AhsanN, Zhang,Xiaoming, Pérez-Pérez,JoséR, Weisenberg,Judy, O'ConnorPrange,Erin, Marsh,EricD, Rajaraman,RajsekarR, Suter,Bernhard, Katyayan,Akshat, Haviland,Isabel, Daniels,Car]
通讯作者:
Daniels,Car
共 9 条
Diagnosis and genotype-phenotype correlations in early life epilepsy and CDKL5 disorder
-
批准号:9893040
-
项目类别:
-
资助金额:$19.82万
-
财政年份:2018
-
负责人:Heather Elisa Olson
-
依托单位:
Diagnosis and genotype-phenotype correlations in early life epilepsy and CDKL5 disorder
-
批准号:10377934
-
项目类别:
-
资助金额:$19.82万
-
财政年份:2018
-
负责人:Heather Elisa Olson
-
依托单位:
海外基金